In the 2024 election, seven out of 10 states passed ballot measures protecting abortion rights. But the effects won't be seen ...

NationsBenefits, a fintech, benefits and outcomes platform, has acquired food-as-medicine company Good Measures, the companies announced Tuesday. Plantation, Florida-based NationsBenefits is a ...

Mobility and transportation challenges make accessing healthcare a daunting endeavor for many individuals who need care. Whether it’s navigating the physical barriers of a doctor’s office ...

According to the U.S. Census Bureau, the entire baby boom generation will be age 65 or older by 2030. Many boomers will move into senior living environments. The National Investment Center for ...

Like many insurers, UnitedHealthcare and Optum are dealing with a surge in digital solutions, according to Dr. Debra Nussbaum, senior director of behavioral health at Optum. And they’re trying ...

Prior authorization has been a bone of contention between payers and providers for some time now. Payers argue that it helps avoid unnecessary care and reduces costs, while providers say it ...

Otsuka Pharmaceutical’s North American CEO —Tarek Rabah — has deep respect for all the entrepreneurs who were at at the annual HLTH conference in Las Vegas touting their capabilities.

An ultra-rare enzyme deficiency that keeps infants from achieving proper muscle function among other developmental delays now has its first FDA-approved treatment. The new product, a gene therapy ...

Halozyme, a biotech firm whose drug delivery technology is a key component of biologic medicines marketed by several big pharma partners, aims to expand its offerings to these customers through ...

As groups across the healthcare sector look to make their work more sustainable, one of the toughest challenges involves life sciences. In the process of creating new drugs and other remedies, the ...

GLP-1 is expected to grow to a $71 billion industry by 2031. GLP-1 medications are fueled by the 66% of Americans who are classified as overweight or obese. No matter what metric, GLP-1 ...

Cancer drug dealmaking is heating up around promising candidates with the potential to top Merck by going after two targets versus the one addressed by the pharmaceutical giant’s blockbuster ...